Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 10 years ago, it would be worth $8,301.91 today based on a price of $165.54 for ASND at the time of writing.

Ascendis Pharma A/S (ASND) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Researchers have found in a 3-year phase 3 trial that palopegteriparatide (TransCon PTH) showed sustained improvements in ...

Novo Nordisk has reported new data with its long-acting human growth hormone (hGH) product Sogroya, showing it is at least as effective as its older drug Norditropin in various paediatric growth ...

As the S&P 500 reaches new highs amid optimism over trade deals and corporate earnings, investors are closely watching the tech sector, which continues to drive market momentum despite concerns about ...

The United States market has shown a robust performance, climbing 1.7% over the past week and 18% in the last year, with earnings projected to grow by 15% annually in the coming years. In this ...

The United States market has shown a positive trajectory with a 1.3% increase over the last week and a 15% climb in the past year, while earnings are projected to grow annually by the same percentage.

Over the last 7 days, the United States market has remained flat, but it has risen by 14% over the past 12 months with earnings expected to grow by 15% per annum in the coming years. In this context ...